Advanced Proteome Therapeutics Corporation (APTCF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | 4597.46 | 2956.30 | 3258.85 | 4216.52 | 5703.06 |
| Gross Profit | - | -4597.46 | -2956.30 | -3258.85 | -4216.52 | -5703.06 |
| Operating Expenses | - | 959.82 Thousand | 673.96 Thousand | 569.93 Thousand | 926.08 Thousand | 1.09 Million |
| Selling, General and Administrative Expenses | - | 272 Thousand | 671.07 Thousand | 566.69 Thousand | 920.19 Thousand | 1.09 Million |
| Research and Development Expenses | - | 687.49 Thousand | 396.49 Thousand | 412.35 Thousand | 621.05 Thousand | 678.78 Thousand |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | - | 959.82 Thousand | 673.96 Thousand | 569.93 Thousand | 926.08 Thousand | 1.09 Million |
| Operating Income | - | -957.36 Thousand | -673.3 Thousand | -569.93 Thousand | -926.08 Thousand | -1.09 Million |
| Interest Expense | - | 29.09 Thousand | 27.4 Thousand | 29.53 Thousand | 22.95 Thousand | 69.85 Thousand |
| Income Tax Expense | - | -133.03 Thousand | -58.32 Thousand | -61.32 Thousand | -104.94 Thousand | -78.26 Thousand |
| Earnings before Tax | - | 597.48 Thousand | -1.92 Million | -541.49 Thousand | -461.36 Thousand | -892.88 Thousand |
| Net Income | - | 759.61 Thousand | -1.83 Million | -450.63 Thousand | -333.46 Thousand | -744.77 Thousand |
| Earnings Per Share Basic | - | 0.01 | -0.06 | -0.02 | -0.02 | -0.05 |
| Earnings Per Share Diluted | - | 0.01 | -0.06 | -0.02 | -0.02 | -0.05 |
| Weighted Average Shares Outstanding | - | 39.08 Million | 31.7 Million | 22.15 Million | 17.28 Million | 14.99 Million |
| Weighted Average Shares Outstanding (Diluted) | - | 39.08 Million | 31.7 Million | 22.15 Million | 17.28 Million | 14.99 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | - | -936.55 Thousand | -648.23 Thousand | -547.61 Thousand | -921.89 Thousand | -1.09 Million |
| Earnings Before Tax Margin | - | - | - | - | - | - |
| Breakdown | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | 124.95 | 1248.68 | 1137.50 |
| Gross Profit | - | - | - | -124.95 | -1248.68 | -1137.50 |
| Operating Expenses | - | - | - | 149.78 Thousand | 286.69 Thousand | 256.32 Thousand |
| Selling, General and Administrative Expenses | - | - | - | 52.62 Thousand | 119.41 Thousand | 80.64 Thousand |
| Research and Development Expenses | - | - | - | 85.35 Thousand | 167.14 Thousand | 175.62 Thousand |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | - | - | - | 149.78 Thousand | 286.69 Thousand | 256.32 Thousand |
| Operating Income | - | - | - | -149.77 Thousand | -286.69 Thousand | -255.75 Thousand |
| Interest Expense | - | - | - | 3773.00 | 11.99 Thousand | 12.9 Thousand |
| Income Tax Expense | - | - | - | -20.34 Thousand | -42.81 Thousand | -35.9 Thousand |
| Earnings before Tax | - | - | - | -1.5 Million | -332.79 Thousand | -258.52 Thousand |
| Net Income | - | - | - | -1.47 Million | -277.98 Thousand | -209.71 Thousand |
| Earnings Per Share Basic | - | - | - | -0.04 | -0.01 | -0.01 |
| Earnings Per Share Diluted | - | - | - | -0.04 | -0.01 | -0.01 |
| Weighted Average Shares Outstanding | - | - | - | 40.71 Million | 40.3 Million | 39.67 Million |
| Weighted Average Shares Outstanding (Diluted) | - | - | - | 40.71 Million | 40.3 Million | 39.67 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | - | - | - | -147.25 Thousand | -285.45 Thousand | -254.58 Thousand |
| Earnings Before Tax Margin | - | - | - | - | - | - |
9247
NGELF
ARGX
FTU
KALO
ISTLTD